The AlexiGen Difference
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident.
Donor Screening and Recovery
The common goal of AlexiGen and its strategic partners is to treat each donor and their family with unmatched honor and respect. We go to extensive lengths when screening, recovering, processing, storing, and distributing donor tissue in order to maximize the benefit for our allograft patients.
Each prospective donor is put through a comprehensive screening process, including medical and social history evaluations that are in accordance with Food and Drug Administration (FDA) regulations and American Association of Tissue Banks (AATB) standards. When screening donors and recovering tissue, the highest standards must be adhered to. After receiving consent from the donor’s family, qualified personnel perform and document a physical examination of the prospective donor. A full review of the donor’s medical records is performed following the physical examination. Upon the final approval of the donor, the donor tissue is then tested by a CLIA certified, FDA-registered laboratory.
These tests include, but are not limited to
the following:
- Anti-HBc
- Anti-HIV Type 1 & 2
- HIV-1 and HCV (NAT)
- Anti-HCV
- HBsAg
- Syphilis
Quality Assurance
Policies are often updated to assure that we are in complete compliance with all applicable standards and regulations. Quality assurance audits are routinely performed on all internal and external processes and procedures. Providing the highest quality biologics to our patients and their physicians is our main focus.
Along with our strategic partners, AlexiGen adheres to strict policies and detailed standard operating procedures in all aspects of the donor screening and tissue recovery process.
Careers
AlexiGen BioTech is committed to collaborating closely with our sales team to enhance their support for physicians, expand business opportunities, and provide cutting-edge care, all aimed at maximizing patient outcomes through our biologics.
